| http://www.w3.org/ns/prov#value | - and, of other NRTIs such as tenofovir and emtricitabine, both of which are potential alternatives to ABC for patients with an elevated risk of cardiovascular disease, and on the other hand, of NNRTIs and protease inhibitors in this and other experimental settings before a sound clinical conclusion can be established.
|
